Log in

Relevant bibliographies by topics / Antiviral effect

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Antiviral effect'

Author: Grafiati

Published: 4 June 2021

Last updated: 30 November 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antiviral effect.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antiviral effect"

1

İNCE KÖSE, Tuğçe, and Ayşe Mine GENÇLER ÖZKAN. "ANTIVIRAL HERBS." Ankara Universitesi Eczacilik Fakultesi Dergisi 46, no. 2 (May 29, 2022): 505–22. http://dx.doi.org/10.33483/jfpau.1057473.

Full text

Abstract:

Objective: Viruses are agents that can infect all kinds of living organisms, and the most important hosts are humans, animals, plants, bacteria and fungi. Viral diseases are responsible for serious morbidity and mortality worldwide, are a major threat to public health, and remain a major problem worldwide. The recently prominent Coronaviruses (CoVs) within this group belong to the Coronaviridae family, subfamily Coronavirinae, and are large (genome size 26−32 kb), enveloped, single-stranded ribonucleic acid (RNA ) viruses that can infect both animals and humans. The world has experienced three epidemics caused by betaCoVs in the last two decades: SARS in 2002−03, MERS in 2012, and COVID-19, first identified in 2019. COVID-19 continues to be our current health problem and studies on the subject continue.Result and Discussion: The term "antiviral agents" is defined in very broad terms as substances other than virus-containing vaccine or specific antibody that can produce a protective or therapeutic effect for the clearly detectable effect of the infected host.Nature has the potential to cure humanity's helplessness against viruses with many different plant species with strong antiviral effects. During the screening of plants with antiviral effects, focusing on plants used in folk medicine is of great importance in terms of maximizing the benefit to humanity - saving time and effort by dealing with valuable ancient knowledge on a scientific basis.In this review, viral diseases and the plants used in these diseases and determined to be effective are mentioned.

APA, Harvard, Vancouver, ISO, and other styles

2

Chandra, Naresh, Lars Frängsmyr, and Niklas Arnberg. "Decoy Receptor Interactions as Novel Drug Targets against EKC-Causing Human Adenovirus." Viruses 11, no. 3 (March 12, 2019): 242. http://dx.doi.org/10.3390/v11030242.

Full text

Abstract:

Epidemic keratoconjunctivitis (EKC) is a severe ocular disease and can lead to visual impairment. Human adenovirus type-37 (HAdV-D37) is one of the major causative agents of EKC and uses sialic acid (SA)-containing glycans as cellular receptors. Currently, there are no approved antivirals available for the treatment of EKC. Recently, we have reported that sulfated glycosaminoglycans (GAGs) bind to HAdV-D37 via the fiber knob (FK) domain of the viral fiber protein and function as decoy receptors. Based on this finding, we speculated that GAG-mimetics may act as artificial decoy receptors and inhibit HAdV-D37 infection. Repurposing of approved drugs to identify new antivirals has drawn great attention in recent years. Here, we report the antiviral effect of suramin, a WHO-approved drug and a widely known GAG-mimetic, against HAdV-D37. Commercially available suramin analogs also show antiviral effects against HAdV-D37. We demonstrate that suramin exerts its antiviral activity by inhibiting the attachment of HAdV-D37 to cells. We also reveal that the antiviral effect of suramin is HAdV species-specific. Collectively, in this proof of concept study, we demonstrate for the first time that virus binding to a decoy receptor constitutes a novel and an unexplored target for antiviral drug development.

APA, Harvard, Vancouver, ISO, and other styles

3

Gao Bin and Yang Gui-zhen. "Immunoregulatory effect and antitumor, antiviral, antivirus activity of polysaccharide." International Journal of Immunopharmacology 13, no. 6 (January 1991): 731. http://dx.doi.org/10.1016/0192-0561(91)90235-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Goldberg, M., L. S. Belkowski, and B. R. Bloom. "Regulation of macrophage growth and antiviral activity by interferon-gamma." Journal of Cell Biology 109, no. 3 (September 1, 1989): 1331–40. http://dx.doi.org/10.1083/jcb.109.3.1331.

Full text

Abstract:

Interferons, in addition to their antiviral activity, induce a multiplicity of effects on different cell types. Interferon (IFN)-gamma exerts a unique regulatory effect on cells of the mononuclear phagocyte lineage. To investigate whether the antiviral and antiproliferative effects of IFN-gamma in macrophages can be genetically dissociated, and whether IFN-alpha and IFN-gamma use the same cellular signals and/or effector mechanisms to achieve their biologic effects, we have derived a series of somatic cell genetic variants resistant to the antiproliferative and/or antiviral activities of IFN-gamma. Two different classes of variants were found: those resistant to the antiproliferative and antiviral effects of IFN-gamma against vesicular stomatitis virus (VSV) and those resistant to the antiproliferative effect, but protected against VSV and encephalomyocarditis virus (EMCV) lysis by IFN-gamma. In addition, a third class of mutants was obtained that was susceptible to the growth inhibitory activity, but resistant to the antiviral activity of IFN-gamma. Analysis of these mutants has provided several insights regarding the regulatory mechanisms of IFN-gamma and IFN-alpha on the murine macrophage cell lines. The antiproliferative activity of IFN-gamma on these cells, in contrast to that of IFN-alpha, is mediated by a cAMP-independent pathway. The antiproliferative and antiviral activities of IFN-gamma were genetically dissociated. Variants were obtained that are growth resistant but antivirally protected, or are growth inhibited but not antivirally protected against VSV or EMCV. The genetic analysis indicated that IFN-alpha and IFN-gamma regulate the induction of the dsRNA-dependent P1/eIF-2 alpha protein kinase and 2',5'-oligoadenylate synthetase enzymatic activities via different pathways. Finally, a unique macrophage mutant was obtained that was protected by IFN-gamma against infection by VSV, but not EMCV, suggesting that antiviral mechanisms involved in protection against these different types of RNA viruses must be distinct at some level.

APA, Harvard, Vancouver, ISO, and other styles

5

Žigrayová, Dominika, Veronika Mikušová, and Peter Mikuš. "Advances in Antiviral Delivery Systems and Chitosan-Based Polymeric and Nanoparticulate Antivirals and Antiviral Carriers." Viruses 15, no. 3 (February 28, 2023): 647. http://dx.doi.org/10.3390/v15030647.

Full text

Abstract:

Current antiviral therapy research is focused on developing dosage forms that enable highly effective drug delivery, providing a selective effect in the organism, lower risk of adverse effects, a lower dose of active pharmaceutical ingredients, and minimal toxicity. In this article, antiviral drugs and the mechanisms of their action are summarized at the beginning as a prerequisite background to develop relevant drug delivery/carrier systems for them, classified and briefly discussed subsequently. Many of the recent studies aim at different types of synthetic, semisynthetic, and natural polymers serving as a favorable matrix for the antiviral drug carrier. Besides a wider view of different antiviral delivery systems, this review focuses on advances in antiviral drug delivery systems based on chitosan (CS) and derivatized CS carriers. CS and its derivatives are evaluated concerning methods of their preparation, their basic characteristics and properties, approaches to the incorporation of an antiviral drug in the CS polymer as well as CS nanoparticulate systems, and their recent biomedical applications in the context of actual antiviral therapy. The degree of development (i.e., research study, in vitro/ex vivo/in vivo preclinical testing), as well as benefits and limitations of CS polymer and CS nanoparticulate drug delivery systems, are reported for particular viral diseases and corresponding antivirotics.

APA, Harvard, Vancouver, ISO, and other styles

6

Chung, Dong-Hoon, Jennifer E. Golden, Robert S. Adcock, Chad E. Schroeder, Yong-Kyu Chu, Julie B. Sotsky, Daniel E. Cramer, et al. "Discovery of a Broad-Spectrum Antiviral Compound That Inhibits Pyrimidine Biosynthesis and Establishes a Type 1 Interferon-Independent Antiviral State." Antimicrobial Agents and Chemotherapy 60, no. 8 (May 16, 2016): 4552–62. http://dx.doi.org/10.1128/aac.00282-16.

Full text

Abstract:

ABSTRACTViral emergence and reemergence underscore the importance of developing efficacious, broad-spectrum antivirals. Here, we report the discovery of tetrahydrobenzothiazole-based compound 1, a novel, broad-spectrum antiviral lead that was optimized from a hit compound derived from a cytopathic effect (CPE)-based antiviral screen using Venezuelan equine encephalitis virus. Compound 1 showed antiviral activity against a broad range of RNA viruses, including alphaviruses, flaviviruses, influenza virus, and ebolavirus. Mechanism-of-action studies with metabolomics and molecular approaches revealed that the compound inhibits host pyrimidine synthesis and establishes an antiviral state by inducing a variety of interferon-stimulated genes (ISGs). Notably, the induction of the ISGs by compound 1 was independent of the production of type 1 interferons. The antiviral activity of compound 1 was cell type dependent with a robust effect observed in human cell lines and no observed antiviral effect in mouse cell lines. Herein, we disclose tetrahydrobenzothiazole compound 1 as a novel lead for the development of a broad-spectrum, antiviral therapeutic and as a molecular probe to study the mechanism of the induction of ISGs that are independent of type 1 interferons.

APA, Harvard, Vancouver, ISO, and other styles

7

Glass, Kathryn, and Niels G. Becker. "Estimating antiviral effectiveness against pandemic influenza using household data." Journal of The Royal Society Interface 6, no. 37 (December 5, 2008): 695–703. http://dx.doi.org/10.1098/rsif.2008.0404.

Full text

Abstract:

Current estimates of antiviral effectiveness for influenza are based on the existing strains of the virus. Should a pandemic strain emerge, strain-specific estimates will be required as early as possible to ensure that antiviral stockpiles are used optimally and to compare the benefits of using antivirals as prophylaxis or to treat cases. We present a method to measure antiviral effectiveness using early pandemic data on household outbreak sizes, including households that are provided with antivirals for prophylaxis and those provided with antivirals for treatment only. We can assess whether antiviral drugs have a significant impact on susceptibility or on infectivity with the data from approximately 200 to 500 households with a primary case. Fewer households will suffice if the data can be collected before case numbers become high, and estimates are more precise if the study includes data from prophylaxed households and households where no antivirals are provided. Rates of asymptomatic infection and the level of transmissibility of the virus do not affect the accuracy of these estimates greatly, but the pattern of infectivity in the individual strongly influences the estimate of the effect of antivirals on infectivity. An accurate characterization of the infectiousness profile—informed by strain-specific data—is essential for measuring antiviral effectiveness.

APA, Harvard, Vancouver, ISO, and other styles

8

Alexander, Paul, and Hana M. Dobrovolny. "Treatment of Respiratory Viral Coinfections." Epidemiologia 3, no. 1 (February 23, 2022): 81–96. http://dx.doi.org/10.3390/epidemiologia3010008.

Full text

Abstract:

With the advent of rapid multiplex PCR, physicians have been able to test for multiple viral pathogens when a patient presents with influenza-like illness. This has led to the discovery that many respiratory infections are caused by more than one virus. Antiviral treatment of viral coinfections can be complex because treatment of one virus will affect the time course of the other virus. Since effective antivirals are only available for some respiratory viruses, careful consideration needs to be given on the effect treating one virus will have on the dynamics of the other virus, which might not have available antiviral treatment. In this study, we use mathematical models of viral coinfections to assess the effect of antiviral treatment on coinfections. We examine the effect of the mechanism of action, relative growth rates of the viruses, and the assumptions underlying the interaction of the viruses. We find that high antiviral efficacy is needed to suppress both infections. If high doses of both antivirals are not achieved, then we run the risk of lengthening the duration of coinfection or even of allowing a suppressed virus to replicate to higher viral titers.

APA, Harvard, Vancouver, ISO, and other styles

9

Zaikonnikova, I. V., A. I. Razumov, G. Kh Gilmanova, G. F. Rzhevskaya, M. B. Vurgaft, M. S. Zarbeyeva, G. A. Savicheva, and A. D. Novitskaya. "Antiviral effect of chlofosphenal." Kazan medical journal 50, no. 4 (March 31, 2022): 55–56. http://dx.doi.org/10.17816/kazmj101107.

Full text

Abstract:

The role of viral infections in the pathology of the visual organ is becoming increasingly important. The etiological role of viruses in diseases of both the outer membranes of the eye (trachoma, conjunctivitis, keratitis) and in diseases of the inner membranes of the eye and the visual pathways (iritis, iridocyclitis, optic neuritis, etc.) has been clarified.

APA, Harvard, Vancouver, ISO, and other styles

10

Benson, J. R., and M. Baum. "Antiviral effect of tamoxifen." Lancet 341, no. 8855 (May 1993): 1288. http://dx.doi.org/10.1016/0140-6736(93)91197-t.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Antiviral effect"

1

Sun, Wai-yin Raymond, and 辛偉賢. "The antitumor and antiviral properties of gold (III) porphyrins and their related complexes." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2004. http://hub.hku.hk/bib/B31245973.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Meza, Benjamin. "The Effect of Cell Type on the Efficacy of CMV Antiviral Drugs." VCU Scholars Compass, 2008. http://scholarscompass.vcu.edu/etd/1567.

Full text

Abstract:

Until recently, all in vitro drug susceptibility assays of cytomegalovirus (CMV) were performed in clinically irrelevant fibroblast cells. This study sought to test if drug susceptibility was affected by cell type. MRC-5 embryonic lung fibroblasts and ARPE-19 retinal pigmented epithelial cells were infected with BADrUL131-Y4 epithelial/fibroblast tropic virus under serial concentrations of ganciclovir (GCV) or maribavir (MBV). Virus was quantified using plaque reduction, GFP fluorescence, and yield reduction. Both drugs performed less efficiently in ARPE-19 cells. A cell type effect was observed for both plaque reduction and yield reduction assays with implications for the treatment of CMV retinitis as well as other manifestations of CMV Disease that involve non-fibroblast cell types.

APA, Harvard, Vancouver, ISO, and other styles

3

Ismail-Cassim, Nazeem. "The effect of short chain fatty acids on picornavirus replication." Thesis, Rhodes University, 1993. http://hdl.handle.net/10962/d1004090.

Full text

Abstract:

Picornavirus proteins VP1 to VP3 are exposed on the surface of the virus particle whereas VP4 is internal and modified at its amino terminus by the addition of myristic acid (Chow et al., 1987; Paul et al., 1987). Myristic acid occupies a position in the core of mature poliovirus particles; it has been suggested that it may be important for particle integrity or in the localization of the capsid protein precursor on the hydrophobic membranes during virion assembly (Chow et al., 1987). To determine the function of the amino-terminal myristylation of VP4 in picornaviruses, and to establish whether competition for the acylation site is a possible approach to antiviral chemotherapy, the effect of fatty acids on virus replication has been examined. Some fatty acids are able to enter picornavirus-infected cells and compete for the myristylation site on VP4. Unexpectedly, it was found that short chain fatty acids also inhibit an early event in the replication of bovine enterovirus (BEV) at concentrations which have no detectable effect on cellular macromolecular synthesis and cloning. These findings indicate that fatty acids inhibit cell-mediated uncoating. Short chain fatty acids inhibit the replication of bovine enterovirus but are almost ineffective against poliovirus type 1, coxsackievirus B5, encephalomyocarditis virus and human rhinovirus lB. Lauric acid binds to bovine enterovirus, thereby stabilizing the virus particle to heat degradation. Fatty acid-bound virions attach to susceptible cells but fail to undergo cell-mediated uncoating. The inhibitory effect is reversible with chloroform and may result from a hydrophobic interaction between the fatty acid and a specific site on the virus particie.

APA, Harvard, Vancouver, ISO, and other styles

4

Marin, Brianna. "Determining the antiviral effect of HSP70 inhibitor, KNK437, by a time-dependent analysis." Walsh University Honors Theses / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=walshhonors1555516450619539.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

McGraw, Thomas L. (Thomas Lee). "The Effect of N, N Bis (ethylene)-P (1-adamantyl) Phosphonic Diamide on Rous Sarcoma Virus." Thesis, North Texas State University, 1988. https://digital.library.unt.edu/ark:/67531/metadc501033/.

Full text

Abstract:

The drug, N,N bis (ethylene)-P (1-adamantyl) phosphonic diamide inhibits focus formation of Rous Sarcoma Virus in tissue culture. Transformation of chick cells was inhibited when the drug was added to chick cells prior to infection. The drug did not inhibit the transformation of Normal Rat Kidney Cells infected with RSV, when the cells were grown at non-permissive temperatures and shifted to permissive temperatures upon addition of the drug. Nor did the drug revert cells transformed at permissive temperatures. These studies indicated that the inhibition of RSV is in the early stage of viral growth, possible penetration or uncoating.

APA, Harvard, Vancouver, ISO, and other styles

6

Isorce, Nathalie. "Du criblage de l’activité antivirale de divers interférons et cytokines pro-inflammatoires contre HBV, vers la description du mécanisme antiviral de l’interleukine-1β dépendant de NF-κB." Thesis, Lyon 1, 2015. http://www.theses.fr/2015LYO10130.

Full text

Abstract:

Dans les patients infectés par HBV, les thérapies avec les analogues de nucléos(t)ides (NAs) ou l'interféron α (IFNα) restent inefficaces pour éradiquer l'infection, à cause d'une forme persistante d'HBV, appelée l'ADN circulaire covalent clos (ADNccc), organisé comme un mini-chromosome. Notre but a été de revisiter l'activité anti-HBV d'un panel de cytokines in vitro en utilisant des hépatocytes non transformés, afin d'identifier de nouvelles options immunothérapeutiques. Parmi toutes les molécules testées, l'IFNβ, l'IFNγ, les IFNλ, le TNFα, l'IL-6, l'IL-1β et le ténofovir (ce dernier utilisé comme contrôle positif) ont montré un effet suppresseur sur la réplication d'HBV aussi fort et parfois plus fort que l'IFNα. La cytokine ayant l'effet le plus élevé sur l'ADN total d'HBV (EC50 ≈ 25 pg/mL), sans cytotoxicité, était l'interleukine-1β (IL-1β), qui est naturellement produite par les cellules de Kupffer (KC), les macrophages du foie. De façon importante, les ARNs totaux d'HBV et l'antigène sécrété HBeAg, mais pas HBsAg, ni l'ADNccc, sont fortement diminués par l'IL-1β. Nous avons donc émis l'hypothèse selon laquelle des promoteurs viraux spécifiques su l'ADNccc pourraient être inhibés, même si l'ADNccc n'est pas dégradé. Ensuite, nous avons étudié le mécanisme de l'activité antivirale de l'IL-1β. Nous avons montré que tous les promoteurs d'HBV sembleraient être inhibés par l'IL-1β. En parallèle, nous avons vérifié que l'IL-1β pouvait activer le promoteur de NF-κB, dont la fonction de transcription a été confirmée. Grâce à cette étude, l'IL-1β a été montré comme ayant un effet antiviral très efficace contre HBV in vitro, par l'intermédiaire de la fixation de NF-κB sur l'ADNccc
In HBV-infected patients, therapies with nucleos(t)ide analogues (NAs) or interferon α (IFNα) remain ineffective in eradicating the infection, because of a persistent form of HBV DNA, namely the covalently closed circular DNA (cccDNA), which is organized as a minichromosome. Our aim was to revisit the anti-HBV activity of a panel of IFNs and pro-inflammatory cytokines in vitro using nontransformed cultured hepatocytes of HBV infection, to identify new immunotherapeutic options. Amongst all molecules tested, IFNβ, IFNγ, IFNλ, TNFα, IL-6, IL-1β and tenofovir showed a suppressive effect on HBV replication at least as strong as, but sometimes stronger than IFNα. The cytokine showing the highest effect on intracellular total HBV DNA without any cytotoxicity, was interleukin-1β (IL-1β), which is naturally produced by Kupffer cells (KC), representing the macrophages of the liver. Importantly, total HBV RNAs and secreted HBeAg, but nor HBsAg, neither cccDNA, were strongly decreased. Thus, we hypothesized that even if cccDNA was not degraded, specific viral promoters on cccDNA could be silenced. Then, we investigated the mechanism of IL-1β antiviral activity. We have shown that all HBV promoters were early inhibited by IL-1β. In the meantime, we have verified that IL-1β can induce nuclear Translocation and expression of NF-κB. We also checked NF-κB functionality. Thanks to this study, IL-1β has been found to have very potent antiviral effect against HBV in vitro, through the binding of NF-κB on cccDNA

APA, Harvard, Vancouver, ISO, and other styles

7

Latham, Sally. "Proteomics to investigate hepatitis C virus infection and the effect of antiviral liposomes on host cells." Thesis, University of Oxford, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.547603.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Somasundaram, Balaji. "A surface plasmon resonance assay to determine the effect of influenza neuraminidase mutations on its affinity with antiviral drugs." Thesis, University of Canterbury. Chemical and Process Engineering, 2013. http://hdl.handle.net/10092/9183.

Full text

Abstract:

The outbreak of pandemic influenza and its ability to spread rapidly makes it a severe threat to public health. Antiviral drugs such as oseltamivir (Roche’s Tamiflu™) and zanamivir (GlaxoSmithKline’s Relenza™) are neuraminidase (NA) inhibitors (NI), which bind more tightly to NA than its natural substrate, sialic acid. However, the virus can acquire resistance to antiviral drugs by developing single point mutations (such as H274Y) in the target protein. Thus in some cases the drugs may not be as effective as expected. The high level of inconsistency exhibited by fluorometric assays and the short half-life of the chemiluminescent assay for monitoring drug resistance lead to the need for a simple, label-free, reliable assay. To address this problem, this work focused on three main objectives: 1) to determine the binding affinities of two common anti-viral drugs (oseltamivir and zanamivir) against the influenza NA wild type and drug resistant mutants using bioinformatics software Schrodinger Suite™ 2010. 2) To develop a reliable label-free, real-time, surface plasmon resonance (SPR) assay to measure the binding affinity between influenza viral coat protein neuraminidase (wild type and mutant) and anti-viral drugs. 3) To develop an SPR inhibition assay to quantitatively compare the interactions of sialic acid, zanamivir and oseltamivir with the viral coat protein neuraminidase (wild type and mutant). The entire docking process was carried out using Schrödinger Suite™ 2010. The 2009 pandemic H1N1 neuraminidase (PDB: 3NSS) was used throughout the docking studies as the wild type structure. Five mutants (H274Y, N294S, H274N, A346N and I222V) and three ligands (sialic acid, oseltamivir and zanamivir) were built using the maestro module. The grid-based ligand docking with energetics (GLIDE) module and induced fit docking (IFD) module were used for docking studies. The binding affinities, Gibbs free energy change (∆G) and molecular mechanics-generalized born energy/ solvent accessible area (MM-GB/SA) values for wild-type NA interactions show that both the antiviral drugs studied interact strongly with the wild-type protein. The ∆G values for all antiviral interactions with mutant NA forms were reduced in magnitude, thereby indicating that they are less favourable than interactions with the wild-type protein. A similar trend was observed with MM-GB/SA results. Amongst all of the computed values, MM-GB/SA was the closest to the experimental data. In several cases, the interactions between the anti-viral drugs and NA mutants were markedly less favourable than those between sialic acid and the same mutants, indicating that these mutations could confer anti-viral resistance. Influenza NA wild-type and H274Y mutant were expressed in baculovirus expression system (BVES) in insect cells. The expressed proteins were partially purified using the standard purification techniques of anion exchange and size exclusion chromatography (SEC). A fluorometric activity assay was performed on the recombinant proteins. Both the wild type and the mutant showed similar level of activities. In addition, the recombinant NAs were used in an inhibition assay. Oseltamivir was found to be sensitive to wild type protein (IC50 = 0.59 nM) and resistant to the H274Y mutant protein (IC50 = 349.43 nM). On the other hand, zanamivir was sensitive to both wild type (IC50 = 0.26 nM) and the H274Y mutant (IC50 = 0.44 nM). This indicated that zanamivir was a more potent inhibitor than oseltamivir. These findings were in good agreement with the literature. An SPR assay for accurate monitoring of influenza antiviral drug resistance was developed. A spacer molecule (1, 6- hexanediamine) was site-specifically tethered to the inert 7-hydroxyl group of zanamivir. The tethered zanamivir was immobilized onto an SPR GLC chip to obtain a final immobilization response of 431 response units (RU). The reference subtracted binding responses obtained for NA wild-type and H274Y mutant were analysed using the ProteOn Manager™ Software tools. The SPR curves were fitted to a simple Langmuir 1:1 model with drift to obtain association rate constant (ka) and dissociation rate constants (kd). The relative binding values obtained from literature and the current SPR assay (1.9 and 1.7 respectively) suggested that the current SPR assay yielded similar results to the existing labelled enzymatic assay. In addition, an SPR inhibition assay was developed. The calculated IC50-spr values were compared and it was observed that oseltamivir was sensitive to wild type protein (IC50-spr = 7.7 nM) and resistant to the H274Y mutant protein (IC50-spr = 256 nM). On the other hand, zanamivir was sensitive to both wild type (IC50-spr = 2.16 nM) and the H274Y mutant (IC50-spr = 2.4 nM). Sialic acid was also found to be sensitive to both wild type (IC50-spr = 5.5 nM) and H274Y mutant (IC50-spr = 3.25 nM). In the cases studied, the viral proteins remained sensitive to sialic acid, consistent with retention of virulence of these mutant strains. It was concluded that zanamivir is a more potent inhibitor than oseltamivir for treating the H274Y mutant. Comparison of the SPR inhibition results with the docking results revealed a similar trend. The wild-type NA and H27Y mutant retained binding affinity for sialic acid and zanamivir. Oseltamivir showed a significant decrease in binding affinity for the H274Y mutant compared with the wild-type. This was because of the disruption of the salt bridge formation within NA that was vital for oseltamivir activity. To my knowledge, this is the first SPR biosensor assay developed to monitor influenza antiviral drug resistance. There is a tremendous scope to extend this study to more mutants and new antiviral drugs. This could pave the way for a reliable SPR biosensor assay to replace low consistency labelled enzymatic assays.

APA, Harvard, Vancouver, ISO, and other styles

9

Gad, Hans Henrik. "Resistance of Chikungunya virus towards the antiviral effect of human 2',5'- oligoadenylate synthetase 3 involves the envelope E2 protein." Paris 7, 2012. http://www.theses.fr/2012PA077068.

Full text

Abstract:

Le virus Chikungunya (CHIKV) est un alphavirus transmis par un moustique responsable d'une série d'épidémies en Afrique et en Asie durant la dernière décennie. Nous avons déjà montré que la 2',5'- oligoadenylate synthétase 3 (OAS3) induite par l'interféron possède une forte activité antivirale contre le CHIKV en empêchant l'accumulation d'ARN viral dans les cellules épithéliales humaines infectées. Dans ce travail, nous avons étudié la capacité du CHIKV a développer des stratégies d'échappement contre l'activité antivirale d'OASS. Par passage série d'un isolât clinique de CHIKV sur des cellules exprimant OAS3, nous avons identifié un variant qui montre une remarquable résistance envers OAS3. L'analyse de l'ARN génomique a permis d'identifier deux substitutions d'acides aminés : dans la protéine non structurale nsP2 et dans la glycoprotéine d'enveloppe E2. Grâce à un clone moléculaire de CHIKV exprimant la Renilla Luciférase, nous avons montré que seul le changement de Glu à Lys en position E2-166 est capable de restaurer la croissance virale dans les cellules humaines exprimant OAS3. L'étude de la croissance virale sur des myoblastes humains, qui sont associés à la pathogénèse du CHIKV, a montré que le CHIKV portant une lysine en position E2-166 se réplique plus efficacement que le virus sauvage. Cette efficacité de réplication accrue dans les myoblastes est associée à une forte phosphorylation de la PKR et d'elF2a suivie par une apoptose plus marquée des cellules. Nos résultats suggèrent que la substitution Glu166Lys dans la protéine E2 permets au CHIKV d'échapper à OAS3 en augmentant la réplication dans les cellules humaines plutôt qu'en agissant en tant que antagoniste
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that has reemerged within the last decade and caused a series of epidemics of unprecedented scale in Africa and Asia. We have previously reported that the interferon-inducible 2',5'-oligoadenylate synthetase 3 (OAS3) exerts potent antiviral activity against CHIKV in human epithelial cells by preventing accumulation of viral RIMA in infected cells. In this study, we investigated whether CHIKV may evolve strategies to circumvent the antiviral effect of OAS3. Through serial passage of a clinical isolate of CHIKV on OAS3-expressing cells, we identified a CHIKV variant which showed remarkable resistance towards OAS3. Analysis of its genomic RNA identified only two unique amino acid substitutions in the nonstructural nsP2 protein and the envelope E2 glycoprotein. Using a molecular clone of CHIKV expressing Renilla luciferase, we showed that only the change from Glu to Lys at position E2-166 was able to rescue viral growth in human cells expressing OAS3. Study of viral growth in human myoblasts, a host cell associated to the pathogenesis of Chikungunya disease, showed that CHIKV bearing Lys in E2-166 was more efficient at replicating in these cells when compared to wild-type virus. The greater efficiency of viral growth in myoblasts was associated with a robust phosphorylation of PKR and elF2a followed by more pronounced apoptotic cell death. Our data suggest that the Glu166Lys substitution in E2 enables CHIKV subversion of OAS3 by promoting viral growth in human cells rather than acting as an antagonist of PAS

APA, Harvard, Vancouver, ISO, and other styles

10

Amankwaah, Collins. "Incorporation of selected plant extracts into edible chitosan films and the effect on the antiviral, antibacterial and mechanical properties of the material." The Ohio State University, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=osu1366220367.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Antiviral effect"

1

G, Gish Robert, ed. Maximizing the benefits of antiviral therapy for HCV: The advantages of treating side effects. Philadelphia: W.B. Saunders, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

S, Weislow Owen, and National Cancer Institute (U.S.), eds. New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. [Bethesda, Md.?: National Cancer Institute, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

S, Weislow Owen, and National Cancer Institute (U.S.), eds. New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. [Bethesda, Md.?: National Cancer Institute, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

S, Weislow Owen, and National Cancer Institute (U.S.), eds. New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. [Bethesda, Md.?: National Cancer Institute, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Abramowicz, Mark. Handbook of antimicrobial therapy. New Rochelle, N.Y: Medical Letter, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Abramowicz, Mark. Handbook of antimicrobial therapy. New Rochelle, N.Y: Medical Letter, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Organisation for Economic Co-operation and Development. Group of National Experts on Safety and Biotechnology. Working Group III, Safety Assessment, Micro-organisms Subgroup., ed. Non-target effects of live vaccines: Langen, Germany, November 3-5, 1993 : proceedings of a workshop / organized by the Organisation for Economic Co-operation and Development (OCDE), Group of National Experts on Safety in Biotechnology, Working Group III, Safety Assessment, Micro-organisms Subgroup. Basel: Karger, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Franck, Boccara, and SpringerLink (Online service), eds. Cardiovascular Disease in AIDS. Milano: Springer Milan, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Potential Treatment for Coronavirus Disease: Antiviral Effect of Medicinal Plant Extracts. Lulu Press, Inc., 2020.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Aiken, Rachel. How to Grow and Use Antiviral Herbs : Antiviral Herbs and Side Effects: Herbal Antivirals. Independently Published, 2022.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Antiviral effect"

1

Puchkova, Ludmila, Mohammad Al Farroukh, Ekaterina Ilyechova, and Irina Kiseleva. "213In Vivo Study of Anti-Influenza Effect of Silver Nanoparticles in a Mouse Model." In Viral and Antiviral Nanomaterials, 213–28. Boca Raton: CRC Press, 2021. http://dx.doi.org/10.1201/9781003136644-14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Motoike, K., S. Hirano, H. Yamana, Tetsuhiko Onda, T. Maeda, and Motozo Hayakawa. "Effect of Processing Conditions of Dolomite on the Antiviral Activity." In Advanced Materials Research, 1125–28. Stafa: Trans Tech Publications Ltd., 2007. http://dx.doi.org/10.4028/0-87849-463-4.1125.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Murreddu, Marta G., Manasa Suresh, Severin O. Gudima, and Stephan Menne. "Measurement of Antiviral Effect and Innate Immune Response During Treatment of Primary Woodchuck Hepatocytes." In Methods in Molecular Biology, 277–94. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-6700-1_24.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Lansky, Ephraim Shmaya Philip, Helena Maaria Paavilainen, and Shifra Lansky. "Antiviral Effects of Acacias." In Acacias, 1–7. Boca Raton: CRC Press, 2023. http://dx.doi.org/10.1201/9780429440946-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Dairpoosh, Farnoosh, and Farnoosh Kianoosh. "Antiviral Effects of Tea." In Therapeutic Perspectives of Tea Compounds, 49–84. Boca Raton: CRC Press, 2023. http://dx.doi.org/10.1201/9781003382652-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Hovanessian, A. G. "Interferons: direct effects upon viral replication." In Approaches to Antiviral Agents, 217–60. London: Palgrave Macmillan UK, 1985. http://dx.doi.org/10.1007/978-1-349-06930-9_8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

dos Santos, André Flores, Mirkos Ortiz Martins, Mariana Zancan Tonel, and Solange Binotto Fagan. "Evaluating the Molecular—Electronic Structure and the Antiviral Effect of Functionalized Heparin on Graphene Oxide Through Ab Initio Computer Simulations and Molecular Docking." In Advances in Bioinformatics and Computational Biology, 25–35. Cham: Springer Nature Switzerland, 2023. http://dx.doi.org/10.1007/978-3-031-42715-2_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Turhan, Munire. "Effects of Extraction Methods Used on Propolis." In Methods of Biochemical Analysis of Bee Products, 141–62. Istanbul: Nobel Tip Kitabevleri, 2024. http://dx.doi.org/10.69860/nobel.9786053359326.8.

Full text

Abstract:

Propolis, a natural biological product obtained from beekeeping, attracts attention with its many aspects, including antibacterial, antifungal, antiviral, antitumoral and anesthetic activity. In addition, due to its very low toxicity, it is used as raw material in industries such as health, food and cosmetics.

APA, Harvard, Vancouver, ISO, and other styles

9

Wong, Grace H. W., and David V. Goeddel. "The Antiviral Effects of Tumor Necrosis Factors." In The Biology of the Interferon System 1986, 273–77. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-3543-3_38.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Farrell, Nicholas. "Antiviral and Antiparasitic Effects of Metal Complexes." In Transition Metal Complexes as Drugs and Chemotherapeutic Agents, 222–42. Dordrecht: Springer Netherlands, 1989. http://dx.doi.org/10.1007/978-94-011-7568-5_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antiviral effect"

1

Kolychikhina, M. S. "Positive effect of preparations with antiviral properties on potato productivity." In Растениеводство и луговодство. Тимирязевская сельскохозяйственная академия, 2020. http://dx.doi.org/10.26897/978-5-9675-1762-4-2020-111.

Full text

Abstract:

In the small-plot experiment of the Russian State Agrarian University - Moscow Timiryazev Agricultural Academy against potato viruses in 2014-2019 were tested some kinds of preparations with antiviral activity: Pharmayod, GS (100 g/l of iodine); Immunocytophyte, TAB (20 g/kg arachidonic acid ethyl ester); Ecogel, WS (30 g/l of chitosan lactate); Amulet, TAB (composition of linear polyaminosaccharides (chitosan) in succinic acid solution); Zerox, WS (3000 mg /l colloidal silver); Viron, WS (biostimulant based on urea and citric acid with the addition of essential oils). According to the results of the studies, it was found that, in addition to the effect on the causative agents of viral diseases of potatoes, all tested preparations had a stable tendency to maintain or increase the yield of tubers of infected plants. The increase in the yield of tubers ranged from 0.5 to 1.3 kg/m2. In 2016 under the production conditions of Astrakhan region on the potato variety Impala infected with the PVM + PVS and PVM + PVS + PVY virus complexes a comparative assessment of the effect of Pharmayod and Immunocytophyte revealed a significant increase in the gross and marketable yield of potato plants in the areas with the use of these preparations compared to with control.

APA, Harvard, Vancouver, ISO, and other styles

2

de Koning, Constance. "Antiviral effect of MAU868 against BK virus prompts further research." In ASN Kidney Week 2022, edited by Rachel Giles. Baarn, the Netherlands: Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/73972a7e.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Pashkovsky, Sergey, Darya Gerne, Aleksandra Zenkova, and Valeria Kurochkina. "Effect of Antiviral Drugs on the Phytoseiulus persimilis Ath.-H. Acariphagus." In Proceedings of the International Scientific Conference The Fifth Technological Order: Prospects for the Development and Modernization of the Russian Agro-Industrial Sector (TFTS 2019). Paris, France: Atlantis Press, 2020. http://dx.doi.org/10.2991/assehr.k.200113.214.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Naumenko, Krystyna, Anna Golovan, Galina Baranova, Svitlana Zagorodnya, Anna Gudz, and Yurii Shermolovych. "Antiviral effect of derivatives of triazoles on EBV-associated lymphoblastoid cells." In 4th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2018. http://dx.doi.org/10.3390/ecmc-4-05612.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Elbashir, Israa, Aisha Aisha Nasser J. M. Al-Saei, Paul Thornalley, and Naila Rabbani. "Evaluation of antiviral activity of Manuka honey against SARS-CoV-2." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2021. http://dx.doi.org/10.29117/quarfe.2021.0113.

Full text

Abstract:

Background and aims: In 2020 a global pandemic was declared caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2). The pandemic is still ongoing and continues to cause considerable mortality and morbidity world-wide and new variants of the virus are emerging. Rapid development and rollout of vaccines for SARS-CoV-2 is in progress to counter the pandemic but has been tempered by the emergence of new SARS-CoV-2 variants, many of which exhibit reduced vaccine effectiveness. To date there is no approved antiviral treatment for coronavirus disease 2019 (COVID-19). Several studies have shown that Manuka honey has virucidal/antiviral effect. Methylglyoxal (MG), a bioactive component in Manuka honey, has antiviral activity in vitro. MG may modify arginine residues in the functional domains of viral spike and nucleocapsid proteins, resulting in loss of charge, protein misfolding and inactivation. The aim of this study was to characterize the antiviral activity of Manuka honey against SARS-CoV-2 in vitro Materials and methods: Wild-type SARS-CoV-2 with titers of multiplicities of infection (MOI) 0.1 and 0.05 were incubated with 2-fold serial dilutions of 250+ Manuka honey (equivalent to 250 to 31 µM) in infection medium (Dulbecco's Modified Eagle Medium + 2% fetal bovine serum + 100 units/ml penicillin + 100 µg/ml streptomycin) for 3 h. Manuka honey treated and untreated control SARS-CoV-2 was incubated with confluent cultures of Vero cells in vitro for 1 h, cultures washed with phosphate-buffered saline and incubated in fresh infection medium at 37°C for 4 - 5 days until 70% of virus control cells displayed cytopathic effect. We also studied the effect of scavenging MG in Manuka Honey with aminoguanidine (AG; 500 µM) on virucidal activity. The antiviral activity of MG was judged by median tissue culture infectious dose (TCID50) assays. Data analysis was by logistic regression. TCID50 (mean ± SD) was deduced by interpolation. Results: Diluted Manuka honey inhibited SARS-CoV-2 replication in Vero cells. SARS-CoV-2 was incubated in diluted Manuka honey in medium at 37°C for 3 h before adding to Vero cells. Manuka honey dilutions down to 125 µM MG equivalents completely inhibited cytopathic effect of SARS-CoV-2 whereas 31.25 µM and 62.5 µM MG equivalents had limited effect. Logistic regression and interpolation of the cytopathic effect indicated that the TCID50 = 72 ± 2 µM MG equivalents for MOI of 0.1. Prior scavenging of MG by addition of AG resulted in virus replication levels equivalent to those seen in the virus control without AG. Conclusion: Manuka honey has antiviral activity against SARS-CoV-2 when incubated with the virus in cell-free media at no greater than ca. 40-fold dilutions of 250+ grade. Anti-viral activity was inhibited by AG, consistent with the anti-viral effect being mediated by MG. Manuka honey dilutions in MG equivalents had similar antiviral effect compared to authentic MG, also consistent with MG content of Manuka honey mediating the antiviral effect. Whilst Manuka honey may inactivate SARS-CoV-2 in cell-free culture medium, its antiviral activity in vivo for other than topical application may be limited because of the rapid metabolism of MG by the glyoxalase system and limited bioavailability of oral MG.

APA, Harvard, Vancouver, ISO, and other styles

6

Cho, WK, MJ Choi, and JY Ma. "In vitro antiviral effect of Cortex Mori Radicis water extracts against influenza viruses." In 67th International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Product Research (GA) in cooperation with the French Society of Pharmacognosy AFERP. © Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-3400416.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Sofia, Carmelo, Liam Edgeway, James Parkin, Lareb S. N. Dean, Yihua Wang, Donna E. Davies, Luca Richeldi, Mark G. Jones, and Matthew Loxham. "The effect of air pollution on the antiviral immune response in pulmonary fibrosis." In ERS Congress 2024 abstracts, PA4453. European Respiratory Society, 2024. http://dx.doi.org/10.1183/13993003.congress-2024.pa4453.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ghanizada, Muzhda, Sofia Malm Tillgren, Mandy Menzel, Louis Praeger-Jahnsen, Nihaya Mahmoud Said, Sisse Ditlev, Nanna Dyhre-Petersen, et al. "Effect of azithromycin on epithelial antiviral immunity in patients with asthma (AZIMUNE-study)." In ERS Congress 2024 abstracts, OA1971. European Respiratory Society, 2024. http://dx.doi.org/10.1183/13993003.congress-2024.oa1971.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Tincati, C., V. Bono, M. Augello, R. Rovito, S. Marozin, A. Santoro, F. Bai, et al. "OC-30 Scant effect of cART on mucosal immune cells during acute HIV infection." In Abstracts from the 16° Italian Conference on AIDS and Antiviral Research. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/sextrans-icar-2024.28.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Abir, Mirazul Mahmud, Yuichi Otsuka, and Yukio Miyashita. "Effects of Composition on Antibacterial and Antiviral Properties of Suspension Plasma-Sprayed Hydroxyapatite/Titania Coating." In ITSC2021, edited by F. Azarmi, X. Chen, J. Cizek, C. Cojocaru, B. Jodoin, H. Koivuluoto, Y. C. Lau, et al. ASM International, 2021. http://dx.doi.org/10.31399/asm.cp.itsc2021p0585.

Full text

Abstract:

Abstract This study investigates the effect of composition on the antibacterial and antiviral properties of hydroxyapatite/titania composite coatings deposited by suspension plasma spraying. Hydroxyapatite is a bioceramic material used as a plasma-sprayed coating to promote osseointegration of femoral stems. TiO2 has promising photocatalytic activity and good efficiency in destroying bacteria, viral species, and parasites. Prior to coating, substrates were grit blasted, ultrasonically cleaned, and heated to enhance adhesion strength. The microstructure of the resulting coatings was then characterized using XRD and Raman spectroscopy. Test results indicated that SPS transformed Ti2O3 into TiO2 with mixed phases. Ti4O7 and Ti3O5 phases were also identified, which show photocatalytic activity due to oxygen vacancies. Antibacterial and antiviral tests were conducted as well.

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Antiviral effect"

1

Tang, Jiqin, Gong Zhang, Jinxiao Xing, Ying Yu, and Tao Han. Network Meta-analysis of Heat-clearing and Detoxifying Oral Liquid of Chinese Medicines in Treatment of Children’s Hand-foot-mouth Disease：a protocol for systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2022. http://dx.doi.org/10.37766/inplasy2022.1.0032.

Full text

Abstract:

Review question / Objective: The type of study was clinical randomized controlled trial (RCT). The object of study is the patients with HFMD. There is no limit to gender and race. In the case of clear diagnosis standard, curative effect judgment standard and consistent baseline treatment, the experimental group was treated with pure oral liquid of traditional Chinese medicine(A: Fuganlin oral liquid, B: huangzhihua oral liquid, C: Lanqin oral liquid, D: antiviral oral liquid, E: Huangqin oral liquid, F: Pudilan oral liquid, G: Shuanghuanglian oral liquid.)and the control group was treated with ribavirin or any oral liquid of traditional Chinese medicine. The data were extracted by two researchers independently, cross checked and reviewed according to the pre-determined tables. The data extraction content is (1) Basic information (including the first author, published journal and year, research topic). (2) Relevant information (including number of cases, total number of cases, gender, age, intervention measures, course of treatment of the experimental group and the control group in the literature). (3) Design type and quality evaluation information of the included literature. (4) Outcome measures (effective rate, healing time of oral ulcer, regression time of hand and foot rash, regression time of fever, adverse reactions.). The seven traditional Chinese medicine oral liquids are comparable in clinical practice, but their actual clinical efficacy is lack of evidence-based basis. Therefore, the purpose of this study is to use the network meta-analysis method to integrate the clinical relevant evidence of direct and indirect comparative relationship, to make quantitative comprehensive statistical analysis and sequencing of different oral liquid of traditional Chinese medicine with the same evidence body for the treatment of the disease, and then to explore the advantages and disadvantages of the efficacy and safety of different oral liquid of traditional Chinese medicine to get the best treatment plan, so as to provide reference value and evidence-based medicine evidence for clinical optimization of drug selection. Condition being studied: Hand foot mouth disease (HFMD) is a common infectious disease in pediatrics caused by a variety of enteroviruses. Its clinical manifestations are mainly characterized by persistent fever, hand foot rash, oral herpes, ulcers, etc. Because it is often found in preschool children, its immune system development is not perfect, so it is very vulnerable to infection by pathogens and epidemic diseases, resulting in rapid progress of the disease. A few patients will also have neurogenic pulmonary edema Meningitis, myocarditis and other serious complications even lead to death, so effectively improve the cure rate, shorten the course of disease, prevent the deterioration of the disease as the focus of the study. In recent years, traditional Chinese medicine has played an important role in the research of antiviral treatment. Many clinical practices have confirmed that oral liquid of traditional Chinese medicine can effectively play the role of antiviral and improve the body's immunity.

APA, Harvard, Vancouver, ISO, and other styles

2

Bunn, Sarah. COVID-19 therapies. Parliamentary Office of Science and Technology, April 2020. http://dx.doi.org/10.58248/rr34.

Full text

Abstract:

This article was updated on 1 May and again on 6 July. Since its original publication on 17 April, the number of COVID-19 clinical trials has increased from 524 to 2,378. There is no cure for COVID-19. Researchers are testing existing drugs to see if they act against SARS-CoV-2 or alleviate the symptoms of the disease. New drugs are also in development, but this is at a very early stage. Results from trials on existing drugs have already been reported with some positive findings. Dexamethasone is a cheap steroid drug that reduces the risk of death of ventilated patients by 35% and by 20% for patients requiring oxygen therapy. Remdesivir is an antiviral drug; there is good evidence that it can reduce the length of time that hospitalised COVID-19 patients are ill. Negative findings are valuable because they allow researchers to focus on other drugs; there is good evidence that hydroxychloroquine does not offer any benefits to treat COVID-19 patients. Research to see if it might have a protective effect for at-risk groups, such as healthcare workers, is ongoing. There are numerous trials in progress to test a range of drugs that act on the immune system.

APA, Harvard, Vancouver, ISO, and other styles

3

Lapidot, Moshe, and Vitaly Citovsky. molecular mechanism for the Tomato yellow leaf curl virus resistance at the ty-5 locus. United States Department of Agriculture, January 2016. http://dx.doi.org/10.32747/2016.7604274.bard.

Full text

Abstract:

Tomato yellow leaf curl virus (TYLCV) is a major pathogen of tomato that causes extensive crop loss worldwide, including the US and Israel. Genetic resistance in the host plant is considered highly effective in the defense against viral infection in the field. Thus, the best way to reduce yield losses due to TYLCV is by breeding tomatoes resistant or tolerant to the virus. To date, only six major TYLCV-resistance loci, termed Ty-1 to Ty-6, have been characterized and mapped to the tomato genome. Among tomato TYLCV-resistant lines containing these loci, we have identified a major recessive quantitative trait locus (QTL) that was mapped to chromosome 4 and designated ty-5. Recently, we identified the gene responsible for the TYLCV resistance at the ty-5 locus as the tomato homolog of the gene encoding messenger RNA surveillance factor Pelota (Pelo). A single amino acid change in the protein is responsible for the resistant phenotype. Pelo is known to participate in the ribosome-recycling phase of protein biosynthesis. Our hypothesis was that the resistant allele of Pelo is a “loss-of-function” mutant, and inhibits or slows-down ribosome recycling. This will negatively affect viral (as well as host-plant) protein synthesis, which may result in slower infection progression. Hence we have proposed the following research objectives: Aim 1: The effect of Pelota on translation of TYLCV proteins: The goal of this objective is to test the effect Pelota may or may not have upon translation of TYLCV proteins following infection of a resistant host. Aim 2: Identify and characterize Pelota cellular localization and interaction with TYLCV proteins: The goal of this objective is to characterize the cellular localization of both Pelota alleles, the TYLCV-resistant and the susceptible allele, to see whether this localization changes following TYLCV infection, and to find out which TYLCV protein interacts with Pelota. Our results demonstrate that upon TYLCV-infection the resistant allele of pelota has a negative effect on viral replication and RNA transcription. It is also shown that pelota interacts with the viral C1 protein, which is the only viral protein essential for TYLCV replication. Following subcellular localization of C1 and Pelota it was found that both protein localize to the same subcellular compartments. This research is innovative and potentially transformative because the role of Peloin plant virus resistance is novel, and understanding its mechanism will lay the foundation for designing new antiviral protection strategies that target translation of viral proteins. BARD Report - Project 4953 Page 2

APA, Harvard, Vancouver, ISO, and other styles

4

Chejanovsky, Nor, and Bruce A. Webb. Potentiation of Pest Control by Insect Immunosuppression. United States Department of Agriculture, January 2010. http://dx.doi.org/10.32747/2010.7592113.bard.

Full text

Abstract:

The restricted host range of many baculoviruses, highly pathogenic to Lepidoptera and non-pathogenic to mammals, limits their use to single or few closely related Lepidopteran species and is an obstacle to extending their implementation for pest control. The insect immune response is a major determinant of the ability of an insect pathogen to efficiently multiply and propagate. We have developed an original model system to study the Lepidopteran antiviral immune response based on Spodoptera littoralis resistance to AcMNPV (Autographa californica multiple nucleopolyhedrovirus) infection and the fascinating immunosuppressive activity of polydnaviruses .Our aim is to elucidate the mechanisms through which the immunosuppressive insect polydnaviruses promote replication of pathogenic baculoviruses in lepidopteran hosts that are mildly or non-permissive to virus- replication. In this study we : 1- Assessed the extent to which and the mechanisms whereby the immunosuppressive Campoletis sonorensis polydnavirus (CsV) or its genes enhanced replication of a well-characterized pathogenic baculovirus AcMNPV, in polydnavirus-immunosuppressedH. zea and S. littoralis insects and S. littoralis cells, hosts that are mildly or non-permissive to AcMNPV. 2- Identified CsV genes involved in the above immunosuppression (e.g. inhibiting cellular encapsulation and disrupting humoral immunity). We showed that: 1. S. littoralis larvae mount an immune response against a baculovirus infection. 2. Immunosuppression of an insect pest improves the ability of a viral pathogen, the baculovirus AcMNPV, to infect the pest. 3. For the first time two PDV-specific genes of the vankyrin and cystein rich-motif families involved in immunosuppression of the host, namely Pvank1 and Hv1.1 respectively, enhanced the efficacy of an insect pathogen toward a semipermissive pest. 4. Pvank1 inhibits apoptosis of Spodopteran cells elucidating one functional aspect of PDVvankyrins. 5. That Pvank-1 and Hv1.1 do not show cooperative effect in S. littoralis when co-expressed during AcMNPV infection. Our results pave the way to developing novel means for pest control, including baculoviruses, that rely upon suppressing host immune systems by strategically weakening insect defenses to improve pathogen (i.e. biocontrol agent) infection and virulence. Also, we expect that the above result will help to develop systems for enhanced insect control that may ultimately help to reduce transmission of insect vectored diseases of humans, animals and plants as well as provide mechanisms for suppression of insect populations that damage crop plants by direct feeding.

APA, Harvard, Vancouver, ISO, and other styles

5

Teixeira, Carla, Caterina Villa, Joana Costa, Isabel M. P. L. V. O. Ferreira, and Isabel Mafra. Edible insects as a source of bioactive peptides. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2023. http://dx.doi.org/10.37766/inplasy2023.3.0075.

Full text

Abstract:

Review question / Objective: This systematic review aimed at performing an exhaustive bibliographic search of all research articles reporting sequenced bioactive peptides obtained from edible insects and the respective properties demonstrated by in silico, in vitro and/or in vivo approaches. This report intends to evaluate the existing weigh-of-evidence regarding each specific claimed bioactive property, thus representing a valuable contribution to the divulgation of the scientific basis on the health benefits associated to the consumption of insects. Condition being studied: Insects are a good source of bioactive peptides (3-20 amino acids residues in length that promote beneficial effects for human health), including antihypertensive, antidiabetic, antioxidant, anti-obesity, immunomodulatory, anti-inflammatory, anti-microbial, antiviral, and antithrombotic properties, among others.

APA, Harvard, Vancouver, ISO, and other styles

6

Morris, Andrew M., Peter Juni, Ayodele Odutayo, Pavlos Bobos, Nisha Andany, Kali Barrett, Martin Betts, et al. Remdesivir for Hospitalized Patients with COVID-19. Ontario COVID-19 Science Advisory Table, May 2021. http://dx.doi.org/10.47326/ocsat.2021.02.27.1.0.

Full text

Abstract:

Remdesivir, a direct-acting antiviral agent, may reduce mortality and progression to mechanical ventilation in moderately ill patients hospitalized with COVID-19 on supplemental low-flow oxygen. The benefits of remdesivir for critically ill patients requiring supplemental oxygen via high-flow nasal cannula or mask, or non-invasive mechanical ventilation, is uncertain. Remdesivir does not benefit and may harm critically ill patients already receiving mechanical ventilation or requiring extra-corporeal membrane oxygenation (ECMO), and it does not provide substantial benefit for hospitalized patients who do not require supplemental oxygen. Remdesivir appears to have comparable effects when used for 5 days or 10 days, and does not appear to be associated with significant adverse effects. Remdesivir is recommended in moderately ill hospitalized patients with COVID-19 requiring supplemental oxygen (Figure 1). Remdesivir may be considered for patients requiring oxygen supplementation via high-flow nasal cannula or mask, or non-invasive mechanical ventilation. It should not be used in critically ill patients on mechanical ventilation or those receiving ECMO. Remdesivir should not be used in patients who do not require supplemental oxygen.

APA, Harvard, Vancouver, ISO, and other styles

7

F, Verdugo-Paiva, Izcovich A, Ragusa M, and Rada G. Lopinavir/ritonavir for the treatment of COVID-19: A living systematic review protocol. Epistemonikos Interactive Evidence Synthesis, January 2024. http://dx.doi.org/10.30846/ies.4f3c02f030.

Full text

Abstract:

Objective To assess the efficacy and safety of lopinavir/ritonavir for the treatment of patients with COVID-19. Design This is the protocol of a living systematic review. Data sources We will conduct searches in the [https://app.iloveevidence.com/loves/5e6fdb9669c00e4ac072701d](L.OVE platform for COVID-19), a system that maps PICO questions to a repository maintained through regular searches in electronic databases, preprint servers, trial registries and other resources relevant to COVID-19. No date or language restrictions will be applied. Eligibility criteria for selecting studies and methods We adapted an already published common protocol for multiple parallel systematic reviews to the specificities of this question. We will include randomised trials evaluating the effect of lopinavir/ritonavir— as monotherapy or in combination with other drugs — versus placebo or no treatment in patients with COVID-19. Randomised trials evaluating lopinavir/ritonavir in infections caused by other coronaviruses, such as MERS-CoV and SARS-CoV, and non-randomised studies in COVID-19 will be searched in case no direct evidence from randomised trials is found, or if the direct evidence provides low- or very low-certainty for critical outcomes. Two reviewers will independently screen each study for eligibility, extract data, and assess the risk of bias. We will perform random-effects meta-analyses and use GRADE to assess the certainty of the evidence for each outcome. A living, web-based version of this review will be openly available during the COVID-19 pandemic. We will resubmit it if the conclusions change or there are substantial updates. Ethics and dissemination No ethics approval is considered necessary. The results of this review will be widely disseminated via peer-reviewed publications, social networks and traditional media. PROSPERO Registration [https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=179212](CRD42020179212) Keywords COVID-19, severe acute respiratory syndrome coronavirus 2, Coronavirus Infections, Systematic review, lopinavir, lopinavir/ritonavir, antivirals

APA, Harvard, Vancouver, ISO, and other styles

8

F, Verdugo-Paiva, Izcovich A, Ragusa M, and Rada G. Lopinavir/ritonavir for COVID-19: A living systematic review. Epistemonikos Interactive Evidence Synthesis, January 2024. http://dx.doi.org/10.30846/ies.4f3c02f030.v1.

Full text

Abstract:

Objective Provide a timely, rigorous, and continuously updated summary of the evidence on the role of lopinavir/ritonavir in the treatment of patients with COVID-19. Methods We conducted searches in the special L.OVE (Living OVerview of Evidence) platform for COVID-19, a system that performs regular searches in PubMed, Embase, CENTRAL, and other 33 sources. We searched for randomized trials and non-randomized studies evaluating the effect of lopinavir/ritonavir versus placebo or no treatment in patients with COVID-19. Two reviewers independently evaluated potentially eligible studies, according to predefined selection criteria, and extracted data using a predesigned standardized form. We performed meta-analyses using randomeffect models and assessed overall certainty in evidence using the GRADE approach. A living, web-based version of this review will be openly available during the COVID-19 pandemic. Results Our search strategy yielded 862 references. Finally, we identified 12 studies, including two randomized trials, evaluating lopinavir/ritonavir, in addition to standard care versus standard care alone in 250 adult inpatients with COVID-19. The evidence from randomized trials shows lopinavir/ritonavir may reduce mortality (relative risk: 0.77; 95% confidence interval: 0.45 to 1.3; low certainty evidence), but the anticipated magnitude of the absolute reduction in mortality, varies across different risk groups. Lopinavir/ritonavir also had a slight reduction in the risk of requiring invasive mechanical ventilation, developing respiratory failure, or acute respiratory distress syndrome. However, it did not lead to any difference in the duration of hospitalization and may lead to an increase in the number of total adverse effects. The overall certainty of the evidence was low or very low. Conclusions For severe and critical patients with COVID-19, lopinavir/ritonavir might play a role in improving outcomes, but the available evidence is still limited. A substantial number of ongoing studies should provide valuable evidence to inform researchers and decision-makers soon Keywords COVID-19, Severe acute respiratory syndrome coronavirus 2, Coronavirus Infections, Systematic review, Lopinavir, Lopinavir/ritonavir, Antivirals

APA, Harvard, Vancouver, ISO, and other styles

9

Wang, X. F., and M. Schuldiner. Systems biology approaches to dissect virus-host interactions to develop crops with broad-spectrum virus resistance. Israel: United States-Israel Binational Agricultural Research and Development Fund, 2020. http://dx.doi.org/10.32747/2020.8134163.bard.

Full text

Abstract:

More than 60% of plant viruses are positive-strand RNA viruses that cause billion-dollar losses annually and pose a major threat to stable agricultural production, including cucumber mosaic virus (CMV) that infects numerous vegetables and ornamental trees. A highly conserved feature among these viruses is that they form viral replication complexes (VRCs) to multiply their genomes by hijacking host proteins and remodeling host intracellular membranes. As a conserved and indispensable process, VRC assembly also represents an excellent target for the development of antiviral strategies that can be used to control a wide-range of viruses. Using CMV and a model virus, brome mosaic virus (BMV), and relying on genomic tools and tailor-made large-scale resources specific for the project, our original objectives were to: 1) Identify host proteins that are required for viral replication complex assembly. 2) Dissect host requirements that determine viral host range. 3) Provide proof-of-concept evidence of a viral control strategy by blocking the viral replication complex-localized phospholipid synthesis. We expect to provide new ways and new concepts to control multiple viruses by targeting a conserved feature among positive-strand RNA viruses based on our results. Our work is going according to the expected timeline and we are progressing well on all aims. For Objective 1, among ~6,000 yeast genes, we have identified 96 hits that were possibly play critical roles in viral replication. These hits are involved in cellular pathways of 1) Phospholipid synthesis; 2) Membrane-shaping; 3) Sterol synthesis and transport; 4) Protein transport; 5) Protein modification, among many others. We are pursuing several genes involved in lipid metabolism and transport because cellular membranes are primarily composed of lipids and lipid compositional changes affect VRC formation and functions. For Objective 2, we have found that CPR5 proteins from monocotyledon plants promoted BMV replication while those from dicotyledon plants inhibited it, providing direct evidence that CPR5 protein determines the host range of BMV. We are currently examining the mechanisms by which dicot CPR5 genes inhibit BMV replication and expressing the dicot CPR5 genes in monocot plants to control BMV infection. For Objective 3, we have demonstrated that substitutions in a host gene involved in lipid synthesis, CHO2, prevented the VRC formation by directing BMV replication protein 1a (BMV 1a), which remodels the nuclear membrane to form VRCs, away from the nuclear membrane, and thus, no VRCs were formed. This has been reported in Journal of Biological Chemistry. Based on the results from Objective 3, we have extended our plan to demonstrate that an amphipathic alpha-helix in BMV 1a is necessary and sufficient to target BMV 1a to the nuclear membrane. We further found that the counterparts of the BMV 1a helix from a group of viruses in the alphavirus-like superfamily, such as CMV, hepatitis E virus, and Rubella virus, are sufficient to target VRCs to the designated membranes, revealing a conserved feature among the superfamily. A joint manuscript describing these exciting results and authored by the two labs will be submitted shortly. We have also successfully set up systems in tomato plants: 1) to efficiently knock down gene expression via virus-induced gene silencing so we could test effects of lacking a host gene(s) on CMV replication; 2) to overexpress any gene transiently from a mild virus (potato virus X) so we could test effects of the overexpressed gene(s) on CMV replication. In summary, we have made promising progress in all three Objectives. We have identified multiple new host proteins that are involved in VRC formation and may serve as good targets to develop antiviral strategies; have confirmed that CPR5 from dicot plants inhibited viral infection and are generating BMV-resistance rice and wheat crops by overexpressing dicot CPR5 genes; have demonstrated to block viral replication by preventing viral replication protein from targeting to the designated organelle membranes for the VRC formation and this concept can be further employed for virus control. We are grateful to BARD funding and are excited to carry on this project in collaboration.

APA, Harvard, Vancouver, ISO, and other styles

10

Gafni, Yedidya, Moshe Lapidot, and Vitaly Citovsky. Dual role of the TYLCV protein V2 in suppressing the host plant defense. United States Department of Agriculture, January 2013. http://dx.doi.org/10.32747/2013.7597935.bard.

Full text

Abstract:

TYLCV-Is is a major tomato pathogen, causing extensive crop losses in Israel and the U.S. We have identified a TYLCV-Is protein, V2, which acts as a suppressor of RNA silencing. Intriguingly, the counter-defense function of V2 may not be limited to silencing suppression. Our recent data suggest that V2 interacts with the tomato CYP1 protease. CYP1 belongs to the family of papain-like cysteine proteases which participate in programmed cell death (PCD) involved in plant defense against pathogens. Based on these data we proposed a model for dual action of V2 in suppressing the host antiviral defense: V2 targets SGS3 for degradation and V2 inhibits CYP1 activity. To study this we proposed to tackle three specific objectives. I. Characterize the role of V2 in SGS3 proteasomal degradation ubiquitination, II. Study the effects of V2 on CYP1 maturation, enzymatic activity, and accumulation and, III. Analyze the effects of the CYP1-V2 interaction on TYLCV-Is infection. Here we describe results from our study that support our hypothesis: the involvement of the host's innate immune system—in this case, PCD—in plant defense against TYLCV-Is. Also, we use TYLCV-Is to discover the molecular pathway(s) by which this plant virus counters this defense. Towards the end of our study we discovered an interesting involvement of the C2 protein encoded by TYLCV-Is in inducing Hypersensitive Response in N. benthamianaplants which is not the case when the whole viral genome is introduced. This might lead to a better understanding of the multiple processes involved in the way TYLCV is overcoming the defense mechanisms of the host plant cell. In a parallel research supporting the main goal described, we also investigated Agrobacteriumtumefaciens-encoded F-box protein VirF. It has been proposed that VirF targets a host protein for the UPS-mediated degradation, very much the way TYLCV V2 does. In our study, we identified one such interactor, an Arabidopsistrihelix-domain transcription factor VFP3, and further show that its very close homolog VFP5 also interacted with VirF. Interestingly, interactions of VirF with either VFP3 or VFP5 did not activate the host UPS, suggesting that VirF might play other UPS-independent roles in bacterial infection. Another target for VirF is VFP4, a transcription factor that both VirF and its plant functional homolog VBF target to degradation by UPS. Using RNA-seqtranscriptome analysis we showed that VFP4 regulates numerous plant genes involved in disease response, including responses to viral and bacterial infections. Detailed analyses of some of these genes indicated their involvement in plant protection against Agrobacterium infection. Thus, Agrobacterium may facilitate its infection by utilizing the host cell UPS to destabilize transcriptional regulators of the host disease response machinery that limits the infection.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!